Ken Griffin
ALLR

Ken Griffin’s Allarity Therapeutics ALLR Stock Holding History

Ken Griffin’s Portfolio ALLR Stock Details ALLR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-84,591
Closed -$91.4K – 12896
2025
Q4 		$91.4K Sell
84,591
-9,551
-10% -$12.2K ﹤0.01% 11710
2025
Q3 		$149K Buy
+94,142
New +$118K ﹤0.01% 11536
2023
Q4 		– Sell
-44
Closed -$19.6K – 14208
2023
Q3 		$19.6K Buy
+44
New +$56.4K ﹤0.01% 12643

Other funds holding ALLR

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Ken Griffin's ALLR Position: Q1 2026 in Review

Ken Griffin sold out of Allarity Therapeutics (ALLR) in Q1 2026, closing a stake of 84,591 shares — an estimated $91.4K sold.

Ken Griffin first reported a position in ALLR in Q3 2023 and held it in 3 quarters. The position peaked at $149K in Q3 2025. 14 funds tracked by Wall St. Rank hold ALLR as of Q1 2026.

  • Ken Griffin reported no remaining Allarity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 84,591 Allarity Therapeutics shares in Q1 2026, an estimated $91.4K.
  • Ken Griffin first reported a position in Allarity Therapeutics in Q3 2023 and held it in 3 quarters.
  • Ken Griffin's Allarity Therapeutics position peaked at $149K in Q3 2025.
  • 14 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.